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Hypertrophic cardiomyopathy (HCM) is characterized by gross cardiac and myocyte hypertrophy, 
myocyte disarray, and interstitial fibrosis. This condition is relatively common, with a prevalence 
of about 1:500 in the general population. Most patients with HCM are either asymptomatic or 
have only minimal symptoms. In general, HCM is a relatively benign disease with an annual 
mortality rate of slightly less than 1% in unselected HCM populations [1,2]. However, sudden 
cardiac death (SCD) may be the first manifestation of the disease. Approximately 60% to 70% of 
all patients with HCM die suddenly [3], and the fatal event is generally assumed, though not 
proven so far, due to ventricular arrhythmias.                                                  
The high arrhythmic propensity in HCM is contributed by a combination of many primary 
substrate abnormalities like hypertrophy, myocardial fibre disarray, interstitial fibrosis etc, and 
possible   secondary   triggers   like   ischemia,   physical   exercise,   and   excessive   sympathetic 
stimulation.   Marked heterogeneity in substrate and triggers would substantially reduce the 
predictive accuracy of any risk stratification model as known to occur in patients with many other 
cardiac arrhythmic conditions. To compound this, heterogeneity in the studied population, low 
event rate, effect of drug therapy etc would also limit the application of any predictive model.   
However, a few revelations in the last decade have contributed to the better understanding of the 
fatal arrhythmia risk. Nonsustained ventricular tachycardia (NSVT) detected on Holter monitoring 
in younger (less than 30 years) patients have been identified to be associated with higher mortality 
rate [4]. Unlike their older counterparts where myocyte loss and fibrosis contribute incrementally 
to arrhythmogenicity, the higher mortality risk in younger patients probably reflects a more potent 
arrhythmogenic substrate caused by myocyte disarray, myocardial ischemia, and abnormal 
autonomic function. No doubt, the association between SCD and NSVT in young patients is 
striking; however, the majority of SCDs, even in young patients, occurred in patients without 
NSVT. This clearly shows that Holter monitoring identifies only a subset of subjects at higher 
risk. Clearly we need to rule out other contributing risk factors before reassuring an individual 
patient based on this non-invasive modality only.                                                 
Is there any role for 12-lead electrocardiogram to predict arrhythmia risk in them? In a cohort of 
patients   with   HCM   selected   because   of   their   high   risk   for   SCD,   none   of   the   studied 
electrocardiographic features (markedly increased voltages, QRS duration, left or rightward QRS 
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axis, abnormal Q waves, and QTc or QT dispersion) did not predict subsequent appropriate 
implantable defibrillator intervention for ventricular tachyarrhythmias and was not useful in risk 
stratification for SCD [5]. Similarly, T wave alternans was also not useful to predict SCD in 
patients with HCM [6].                                                                                             
Another   possible   predictor   could   be   exercise-induced   arrhythmias.   Though   occurrence   of 
ventricular arrhythmias during exercise is rare in HCM, its presence has long been identified to be 
associated with an increased  SCD risk. In a recent study, the presence  exercise-induced 
nonsustained VT or ventricular fibrillation was associated with a 3.73-fold increase in the risk of 
SCD or hemodynamically compromising sustained VT during follow-up [7].                      
Of late, a few studies with cardiac magnetic resonance (CMR) imaging in HCM also have shown 
some promising insights into risk stratification [8-12]. Delayed enhancement in CMR in HCM 
correlates with the histological finding of fibrosis and thus represents a likely substrate for 
ventricular tachyarrhythmias. In asymptomatic or mildly symptomatic HCM patients this finding 
in CMR had a significantly increased frequency of ventricular tachyarrhythmias on Holter 
monitoring   compared   with   those   without   it.   However,   larger   studies   are   required   before 
establishing the role this non-invasive tool in the risk stratification in HCM.                                 
Is there a role of genotype in deciding risk of SCD in these patients? Since the discovery of first 
causal gene and mutation for HCM in 1990, more than a dozen sarcomeric genes have been 
implicated in this disease [13]. Of these, certain mutations are considered high risk - for example, 
most mutations in TNNT2, R719Q and R403Q in MYH7, and double-causal mutations. However, 
a myriad of genetic (modifier genes, microRNAs, post-translational modifications of proteins, 
epigenetic factors etc) and nongenetic factors interplay to result in the complex phenotype in 
HCM. So a predictive model to assess the global risk of SCD in HCM based on genotype alone is 
still far from reality.                                                                                                   
In conclusion, despite being half a century down the initial detailed clinical description of the 
entity, the predictors of fatal arrhythmias in this disease still remain largely elusive. However, in 
future, more advanced research into the causal genes and genotype-phenotype correlation, and 
larger natural history studies may likely enable us to predict the arrhythmia risk in HCM in a 
better way.                                                                                                              
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